Brief: Shenzhen Hepalink Pharmaceutical Says Inhixa Obtains Approval In North Macedonia
13/04/2021 11:28
April 13 (Reuters) - Shenzhen Hepalink Pharmaceutical Group
Co Ltd 002399.SZ :
* SHENZHEN HEPALINK PHARMACEUTICAL- INHIXA OBTAINS APPROVAL
FROM
AGENCY FOR MEDICINES AND MEDICAL DEVICES IN NORTH MACEDONIA
Source text for Eikon: urn:newsml:reuters.com:*:nHKS4HBHq4
Further company coverage: 002399.SZ
(Reporting by Arundhati Dutta)
((Arundhati.Dutta@thomsonreuters.com; +918067492529;))
Recent news on Shenzhen Hepalink Pharmaceutical Co
See all newsBrief: Shenzhen Hepalink Pharmaceutical Group Says Enoxaparin Sodium Injection Obtains New Manufacturer Authorization From EMA
Brief: Shenzhen Hepalink Pharmaceutical Group Posts QTRLY Net Profit Attributable Of RMB156.6 Million
Brief: Shenzhen Hepalink Pharmaceutical Posts Profit Attributable RMB646.7 Million For Year
Brief: Shenzhen Hepalink Pharmaceutical Says Enoparin Approved In Argentina
Brief: Shenzhen Hepalink Pharmaceutical Says H1710 Injection Received Approval For From NMPA